Teva (NYSE: TEVA) CEO exercises RSUs, sells 20,025 shares for tax withholding

Rhea-AI Filing Summary

Teva Pharmaceutical Industries President and CEO Richard Francis reported vesting and related transactions in company equity on March 5, 2026. He exercised 42,452 Restricted Share Units (RSUs), which converted into the same number of ordinary shares at a stated price of $0.00 per share.

Following the RSU conversion, he held 1,190,664 ordinary shares before selling 20,025 ordinary shares in open-market transactions at a weighted average price of $31.6684 per share to cover tax withholding obligations. After these sales, he directly owns 1,170,639 ordinary shares and 127,359 RSUs, each RSU representing a contingent right to one ordinary share or its cash value. The sale was made under a pre-arranged Rule 10b5-1 trading plan. Ordinary shares may be represented by American Depositary Shares on a one-for-one basis.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Francis Richard D

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/05/2026		M		42,452	A	(2)	1,190,664	D
Ordinary Shares(1)	03/05/2026		S(3)		20,025(4)	D	$31.6684(5)	1,170,639	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	03/05/2026		M			42,452	(6)	(6)	Ordinary Shares(1)	42,452	$0	127,359	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.

4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

6. Restricted share units were granted on March 5, 2025, with 42,452 vested on March 5, 2026, 42,452 vesting on each of March 5, 2027 and March 5, 2028, and 42,455 vesting on March 5, 2029.

	/s/ Dov Bergwerk as attorney-in-fact for Richard D. Francis	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Teva (TEVA) CEO Richard Francis report on March 5, 2026?

Teva CEO Richard Francis reported RSU vesting and a related share sale on March 5, 2026. He exercised 42,452 restricted share units into ordinary shares, then sold 20,025 ordinary shares in open-market transactions while retaining over 1.17 million shares and 127,359 RSUs.

How many Teva (TEVA) shares did the CEO sell, and at what price?

Richard Francis sold 20,025 Teva ordinary shares in open-market transactions at a weighted average price of $31.6684 per share. The transactions occurred within a price range from $31.26 to $32.34, as disclosed, and were executed to cover tax withholding obligations.

Were Teva (TEVA) CEO Richard Francis’s share sales under a Rule 10b5-1 plan?

Yes. The filing states the March 5, 2026 transactions were effected under a Rule 10b5-1 trading plan. That pre-arranged plan was adopted by Richard Francis on November 14, 2025, providing a structured, pre-scheduled framework for executing these tax-related sales.

What Teva (TEVA) equity awards vested for the CEO in this Form 4 filing?

The filing shows 42,452 Restricted Share Units vested for Richard Francis on March 5, 2026. Each RSU represents a contingent right to receive one ordinary share, or at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share at settlement.

How many Teva (TEVA) shares and RSUs does the CEO hold after these transactions?

After the reported transactions, Richard Francis directly owns 1,170,639 Teva ordinary shares and 127,359 Restricted Share Units. These RSUs are scheduled in multiple vesting tranches through March 5, 2029, with each unit linked to one ordinary share or its cash equivalent at settlement.

How are Teva (TEVA) Restricted Share Units structured for the CEO?

Each Restricted Share Unit for Richard Francis represents a contingent right to receive one ordinary share at settlement or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. RSUs were granted March 5, 2025, vesting annually from 2026 through 2029.